Navigation Links
Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
Date:2/27/2008

llion, the majority of which are derived from the three largest markets; France, the United Kingdom and Germany.

Revenues from Asia Pacific were $170.9 million for the three months ended December 31, 2007 and were derived from Mylan's newly acquired operations in Australia, Japan and New Zealand.

For the Specialty Segment, total revenues for the three months ended December 31, 2007 were $102.1 million. The Specialty Segment consists of the Dey business that focuses on the development, manufacturing and marketing of specialty pharmaceuticals in the respiratory and severe allergy markets.

The Matrix Segment reported total revenues of $107.1 million, of which $92.9 million represents sales to third parties.

Gross profit for the three months ended December 31, 2007 was $356.1 million and gross margins were 30.8%. The decrease in gross margins is due primarily to the effects of purchase accounting items recorded during the quarter of approximately $117.7 million, which consisted primarily of amortization related to purchased intangible assets and the amortization of the inventory step-up associated with the acquisition of Merck Generics. Excluding such items, gross margins were 41.0% compared to 55.9% for the three months ended December 31, 2006.

The Company reported a loss from operations of $1.27 billion for the three months ended December 31, 2007. This loss from operations for the quarter included a $1.27 billion one-time charge to write-off acquired in-process research and development, which is recorded without a tax effect, and excludes the $117.7 million of purchase accounting items discussed above. Excluding these amounts, earnings from operations would have been $118.5 million, a decrease of $65.1 million from the prior year.

Research and development ("R&D") expense for the three months ended December 31, 2007 was $80.8 million compared to $22.9 million in the same prior year period. R&D expense includes approximately $5
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
2. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
3. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
4. Mylan Restores Availability of Generic Levothyroxine in Florida
5. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
6. Mylan Declares Quarterly Preferred Stock Dividend
7. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
8. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
9. Mylan Sets Date of 2008 Annual Meeting
10. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
11. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Effective today, the wellness ... Highmark Blue Cross Blue Shield Insurance. Owned by ... Nourish Nutrition and Health opened for business earlier ... Wexford. , The basis of the services ... informing clients on the simplicity of leading a ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 A ... business and technology startups is now available from ... marketing agency based in the Chicago region. The ... software and information technology (IT), services, ecommerce, healthcare, ... , Marketing disciplines critical to startup success include ...
(Date:7/30/2014)... Printing whole new organs for transplants sounds like something ... technology could one day make actual kidneys, livers, hearts ... In the ACS journal Langmuir , scientists are ... that takes them a step closer to realizing their ... , Yong Huang and colleagues note that this idea ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The 3D ... seen and touched in our new 50,000 square foot ... (just behind Target). , Projectorscreenstore.com is one of the ... range of sophisticated technology and Audio/Visual products for education, ... with Makerbot, the leading manufacturer of 3D printers for ...
(Date:7/30/2014)... July 30, 2014 The Hearing Aid ... five years to 2014. Following a multiyear drop during ... demographic trends, the expansion of private healthcare coverage and, ... that Hearing Aid Clinics industry revenue will ... billion during the five years to 2014. , According ...
Breaking Medicine News(10 mins):Health News:Nourish Nutrition and Health Now Accepting Highmark Insurance 2Health News:Startup Marketing Practice Launched by Modern Marketing Partners 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3
... in the topoisomerase II alpha ( TOP2A ) gene ... compared with non-anthracycline-based regimens, according to a study in ... of the National Cancer Institute. The increased responsiveness ... tumors carry an amplification of the HER 2 ...
... Health & Science University Knight Cancer Institute will evaluate ... Seattle, Wash.) is as effective in delivering highly precise ... it has been in those with prostate cancer. , ... for prostate cancer, and it is our hope to ...
... Senior Living, Inc. (NYSE: SRZ ) today ... its Bank Credit Facility, which eliminates all financial covenants, ... 2009 maturity date."We are very pleased that our bank ... through its maturity date," said Mark Ordan, Sunrise,s chief ...
... NSAIDs can cause liver or stomach illness in ... (HealthDay News) -- Many over-the-counter painkillers and fever ... the potential danger of liver damage and stomach ... will have to include these warnings on all ...
... of the American Academy of Disaster Medicine,s (AADM), Gary ... from a disaster medicine perspective on the recent swine ... why improvements are needed to the U.S. public health ... or pathogen; how disaster medicine specialists are helping other ...
... Smithfield Foods, Inc. (NYSE: SFD ) ... no clinical signs or symptoms of the presence of ... its employees at its joint ventures in Mexico. As ... officials and are submitting samples from their swine herds ...
Cached Medicine News:Health News:Gene alterations associated with response to anthracycline therapy for breast cancer 2Health News:OHSU Knight Cancer Institute to study new radiation technology for head, neck cancer 2Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 2Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 3Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 4Health News:FDA Adds New Label Warnings to Over-the-Counter Painkillers 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 3Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 4Health News:Smithfield Foods Says North American Influenza Not Present in Any of Its Worldwide Operations and Pork is Safe to Eat 2
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... 2014  DigiPath, Inc. (OTCBB and OTCQB: DIGP), a ... cannabis testing and education markets, announced today that has ... not previously disclosed or, to its knowledge, any other ... "We have noticed unusual price and volume ... days," said Steve Barbee , CEO of DigiPath. ...
(Date:7/30/2014)... Coordinators, Inc. (PCI) is pleased to announce it has ... Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, ... Kingdom and operates regional offices in ... Tokyo , Japan. Penn Pharma offers both drug development ... manufacturing, as well as Clinical Packaging, Labeling, and global ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... FDA approved Makena (hydroxyprogesterone caproate) in February 2011 ... births in women who have had at least one ... approved, a version of the active ingredient of Makena ... drug from a pharmacist who compounded the drug.  In ...
... N.J., Nov. 8, 2011 Covance Inc. (NYSE: ... Credit Suisse Healthcare Conference on Thursday, November 10, 2011 at ... the presentation at www.covance.com .  In order to register ... early. Covance, with headquarters in Princeton, New Jersey, ...
Cached Medicine Technology:FDA Statement on Makena 2Covance to Present at Credit Suisse 2011 Healthcare Conference 2
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
Medicine Products: